CGON
CG Oncology, Inc. Common stockKey Statistics
About CG Oncology, Inc. Common stock
CG Oncology, Inc. is a clinical-stage biotechnology company focused on innovating cancer therapies, with its lead asset, CG0070, being an oncolytic virus therapy designed specifically for non-muscle invasive bladder cancer. The company's strategic commitment to addressing significant unmet needs in oncology emphasizes its potential impact on patient outcomes and treatment paradigms. As CG Oncology progresses through clinical trials and approaches key regulatory milestones, it leverages its proprietary platform to position itself favorably in the competitive oncology landscape. This strategic focus on pioneering therapeutic solutions presents a compelling opportunity for institutional investors seeking to invest in transformative advancements in cancer care.
Fundamentals
| Revenue (TTM) | $4.04M |
| Gross Profit (TTM) | $-117.25M |
| EBITDA | $-189.33M |
| Operating Margin | -2097.00% |
| Return on Equity | -21.70% |
| Return on Assets | -15.40% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $9.33 |
| Price-to-Book | 7.57 |
| Price-to-Sales (TTM) | 1432.89 |
| EV/Revenue | 1228.35 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 409.20% |
| Shares Outstanding | $84.44M |
| Float | $69.04M |
| % Insiders | 0.65% |
| % Institutions | 111.36% |
Historical Volatility
Volatility is currently contracting